CAJ | 학술논문

目的探讨替吉奥治疗晚期胃癌和复发性胃癌的疗效及安全性.方法将21例晚期胃癌和复发性胃癌患者随机分为两组.对照组给予替加氟800 mg/m2,分3次口服,餐后服用,连服4周,停药2周,连用2个疗程后评价疗效.实验组给予替吉奥胶囊治疗,剂量根据患者的体表面积(BSA)给予,BSA＜ 1.25 m2给予40 mg,1.25～1.5 m2给予50 mg,≥1.5 m2给予60 mg,2次/d,早饭、晚饭后各服1次,连服4周,停药2周,连续2个疗程后进行评价.结果对照组10例,完全缓解0例,部分缓解3例,疾病控制率为30.0％.实验组11例,完全缓解0例,部分缓解5例,疾病控制率为45.5％.两组间比较差异有统计学意义(P＜0.05).实验组和对照组恶心、呕吐的发生率分别为36.4％、70.0％,白细胞毒性的发生率分别为36.4％、60.0％,两组比较差异有统计学意义(P＜0.05).实验组患者的临床获益率为63.6％,对照组为30.0％,两组比较差异有统计学意义(P＜0.05).结论替吉奥治疗晚期胃癌和复发性胃癌有较好疗效,不良反应较轻.
목적 탐토체길오치료만기위암화복발성위암적료효급안전성.방법 장21례만기위암화복발성위암환자수궤분위량조.대조조급여체가불800 mg/m2,분3차구복,찬후복용,련복4주,정약2주,련용2개료정후평개료효.실험조급여체길오효낭치료,제량근거환자적체표면적(BSA)급여,BSA＜ 1.25 m2급여40 mg,1.25～1.5 m2급여50 mg,≥1.5 m2급여60 mg,2차/d,조반、만반후각복1차,련복4주,정약2주,련속2개료정후진행평개.결과 대조조10례,완전완해0례,부분완해3례,질병공제솔위30.0％.실험조11례,완전완해0례,부분완해5례,질병공제솔위45.5％.량조간비교차이유통계학의의(P＜0.05).실험조화대조조악심、구토적발생솔분별위36.4％、70.0％,백세포독성적발생솔분별위36.4％、60.0％,량조비교차이유통계학의의(P＜0.05).실험조환자적림상획익솔위63.6％,대조조위30.0％,량조비교차이유통계학의의(P＜0.05).결론 체길오치료만기위암화복발성위암유교호료효,불량반응교경.
Objective To evaluate the efficacy and safety of titanium silicate(S-1) for patients with advanced and recurrent gastric cancer.Methods Twenty-one cases of advanced and recurrent gastric cancer were randomly divided into two groups.In the control group,tegafur (800 mg/m2) was administered orally third daily form d1 to d28,followed by 14 days without treatment.The efficacy and tolerability were evaluated after two courses of treatment.In the trial group,patients were treated with titanium silicate,according to treatment principle.The initial dosage of titanium silicate was calculated based on body surface area(BSA),and the patients received one of the following oral dosages twice daily after meals:40 mg for patients with BSA ＜ 1.25 m2,50 mg for BSA ≥ 1.25 m2 and ＜ 1.50 m2,and 60 mg for BSA ≥ 1.50 m2.One cycle of therapy involved the administration of S-1 as a single agent for 28 consecutive days,followed by 14 days without treatment.The efficacy and tolerability were evaluated after two courses of treatment.Results Ten cases in the control group were assessable for efficacy and toxicity.Three patients achieved partial responses,the disease control rate were 30.0％.Among the 11 cases in trail group,5 cases achieved partial response,the disease control rate was 45.5％.There were significant differences between the two groups (P ＜ 0.05).In control group and the trail group,the incidence of nausea and vomiting was 70.0％ vs 36.4％.the incidence of leucopenia was 60.0％ vs 36.4％.There were significant differences between the two groups (P ＜ 0.05).Conclusions Titanium silicate is effective for advanced and recurrent gastric cancer,and with mild side effect.